Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Abstract

DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. (Funded by AstraZeneca and Bristol-Myers Squibb; SAVOR-TIMI 53 ClinicalTrials.gov number, NCT01107886.).

Keywords

SaxagliptinMedicineHazard ratioMyocardial infarctionInternal medicineHeart failurePlaceboStroke (engine)Type 2 diabetesUnstable anginaClinical endpointDiabetes mellitusConfidence intervalRandomized controlled trialSitagliptinEndocrinology

Affiliated Institutions

Related Publications

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott , Itamar Raz , Marc P. Bonaca +17 more

In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MAC...

2018 New England Journal of Medicine 5890 citations

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green , M. Angelyn Bethel , Paul W. Armstrong +16 more

Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular ...

2015 New England Journal of Medicine 2519 citations

Cardiovascular Actions of Incretin-Based Therapies

John R. Ussher , Daniel J. Drucker

Glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors represent 2 distinct classes of incretin-based therapies used for the treatment ...

2014 Circulation Research 335 citations

Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors

Michael A. Nauck

Over the last few years, incretin‐based therapies have emerged as important agents in the treatment of type 2 diabetes ( T2D ). These agents exert their effect via the incretin ...

2015 Diabetes Obesity and Metabolism 411 citations

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

John J.V. McMurray , David L. DeMets , Silvio E. Inzucchi +9 more

Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes wh...

2019 European Journal of Heart Failure 430 citations

Publication Info

Year: 2013
Type: article
Volume: 369
Issue: 14
Pages: 1317-1326
Citations: 3396
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3396

OpenAlex

Cite This

APA Style

                            
                                
                                    Benjamin M. Scirica, 
                                
                                    Deepak L. Bhatt, 
                                
                                    Eugene Braunwald
                                
                                et al.
                            
                            (2013). 
                            Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. 
                            New England Journal of Medicine
                            , 369
                            (14)
                            , 1317-1326.
                            https://doi.org/10.1056/nejmoa1307684
                        

Identifiers

DOI: 10.1056/nejmoa1307684